Phase II Trial of Vatalanib in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma After First-Line Gemcitabine Therapy (PCRT O4-001)

Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-014-2499-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Gemcitabine and Oxaliplatin (GEMOX) in Gemcitabine Refractory Advanced Pancreatic Adenocarcinoma: A Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2006English

Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2018English

Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2009English

Gemcitabine Combined With Capecitabine Compared to Gemcitabine With or Without Erlotinib as First-Line Chemotherapy in Patients With Advanced Pancreatic Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2014English

Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial

Breast Care
SurgeryOncology
2011English

A Phase I Study of Imexon Plus Gemcitabine as First-Line Therapy for Advanced Pancreatic Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2009English

Phase I/Ii Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)

Targeted Oncology
Cancer ResearchOncologyPharmacology
2016English

Clinical Trial Simulations Based on a Meta-Analysis of Studies in Patients With Locally Advanced and/or Metastatic Adenocarcinoma Pancreatic Cancer Receiving Gemcitabine (GEM) Alone or in Combination

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy